Psyence Biomedical Ltd. · NASDAQ:PBM
Psyence Biomedical — SPAC Merger (January 2024)
28 slides from Psyence Biomedical's SPAC merger presentation, Jan 16, 2024
Slide 1: Corporate Presentation: Proposed Business Combination with Newcourt Acquisition Corporation
Corporate Presentation Proposed Business Combination with Newcourt Acquisition Corporation January 2024
Slide 2: Disclaimer
2 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature This presentation (this “Presentation”) does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes . The information contained in this Pr
Slide 3: Forward-Looking Statements and Industry Data
3 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature The foregoing list of factors is not exhaustive . You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement refere
Slide 4: Summary Transaction Overview
4 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Summary Transaction Overview Overview • Psyence and its subsidiary Psyence Biomed Corp. signed a Business Combination Agreement on January 9th 2023, to combine with Newcourt Acquisition Corp, ( Nasdaq:NCAC ) (“Newcou
Slide 5: Psyence Biomedical Ltd Strategic Value Drivers
5 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence Biomedical Ltd Strategic Value Drivers • Simple and Focused Business • Licensed IP protected Psilocybin Drug with exclusivity in USA, EU and UK • Initiate a Phase IIb Clinical Trial in Australia to develop a
Slide 6: Transaction Overview
6 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Transaction Overview 1,2,3,4,5,6,7 Pro Forma Valuation PF Shares Outstanding (M) 13.2 Share Price ($) $10.0 PF Equity Value ($M) $132.0 (+) PF Debt ($M) $1.8 ( - ) PF Cash ($M) ($22.8) PF Enterprise Value ($M) $111 P
Slide 7: Executive Summary
7 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Executive Summary Newcourt Acquisition Corp and Psyence entered into an Amended and Restated Business Combination Agreement on July 31st, 2023 • The Resulting cash in the Combined Company is anticipated to be approxi
Slide 8: Acquisition Target
8 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Acquisition Target
Slide 9: Psyence Biomedical Ltd is changing the face of Palliative Care treatment
9 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence Biomedical Ltd is changing the face of Palliative Care treatment Naturally Derived Plant based Psilocybin Accelerated Outsourced drug Development Ph IIb Ph III $10.4B USD Projected Size of Cancer Palliative C
Slide 10: Large Palliative Care Market with Robust Projected CAGR
10 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Large Palliative Care Market with Robust Projected CAGR *Source: Global Psychedelic Therapeutics Market (insightaceanalytic.com) Cancer $10.4B* Other Disease $18.2B* Projected Global Palliative Care Market $28.6B wi
Slide 11: Palliative Care and Nature based: Key Differentiators within Psychedelic Sector
11 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Palliative Care and Nature based: Key Differentiators within Psychedelic Sector Psyence Psychedelic Sector ** • First mover in Palliative Care • Phase IIb Ready • Pioneering Natural Psilocybin (Plant derived) vs Syn
Slide 12: Advantages of the Development of Biological Drugs
12 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Advantages of the Development of Biological Drugs Differentiated FDA Pathway Differentiated FDA Pathway with benefits as defined by t
Slide 13: Psyence's Intellectual Property within Drug development
13 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence’s Intellectual Property within Drug development Regulatory Protection Data and Marketing Exclusivity: • First indication with Molecule will be granted protection from any generic entry for periods up to 10 y
Slide 14: Anticipated Developmental Pathway to Approval
14 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Q2 2023 H1 2025 H2 2025 FDA Pre - IND Feedback Received HREC approval Phase IIb in Adjustment Disorder First patient Randomised Last patient Last visit Top Line Results Planned End of Phase II meeting with FDA FDA I
Slide 15: Patient Safety and Efficacy Enhanced by Psilocybin-Assisted Psychotherapy
15 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Patient Safety and Efficacy Enhanced by Psilocybin - Assisted Psychotherapy (PAP) *Brennan W and Belser AB (2022), Models of Psychedelic - Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMB
Slide 16: Psyence Phase IIa protocol approved for Human use in the UK
16 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence Phase IIa protocol approved for Human use in the UK September 2022 (paused) • Our first clinical trial protocol using PEX010 for the treatment of Adjustment Disorder was been approved by MHRA (Medicines and
Slide 17: Australia Clinical Trial Phase IIb
17 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Australia Clinical Trial Phase IIb Psyence’s clinical trial program is focused on assessing the safety and efficacy of psilocybin - assisted psychotherapy for the treatment of adjustment disorder* due to an incurabl
Slide 18: Psyence Well-Positioned for Value Growth
18 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature $50 $35 $68 $72 $129 $339 $378 Average $170 $50 $79 $90 $119 $241 $454 $542 Average $254 (USD $M) 1,3 Psyence Well - Positioned for Value Growth (1) • Valuation range can be estimated by comparing Psyence to related
Slide 19: Selected Clinical Stage Psychedelic Comparable Company Market Data
19 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Selected Clinical Stage Psychedelic Comparable Company Market Data (1,2) 9/14/2023 ($ in millions, except per share data) GH Research PLC NasdaqGM:GHRS $10.42 $542 $378 1 COMPASS Pathways plc NasdaqGS:CMPS $9.92 $45
Slide 20: Selected Clinical Stage Psychedelic Comparable Company Descriptions
20 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Selected Clinical Stage Psychedelic Comparable Company Descriptions (1) Source : S&P CapitalIQ , Company Filings 1. Market data reflective as of the close on 9 / 14 / 2023 , the valuations listed on this slide refle
Slide 21: Psychedelics Research Gaining Acceptance and Momentum: Potential Market Disruptor
21 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psychedelics Research Gaining Acceptance and Momentum: Potential Market Disruptor
Slide 22: Management Team
22 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Dr. Neil Maresky CEO • Trained MD in Emergency Medicine and Family Practice • VP Scientific Affairs AstraZeneca Canada Inc, Previously at Wyeth, Bayer • 25+ years of experience leading Research and Development for B
Slide 23: Psyence Biomed Board of Directors
23 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Psyence Biomed Board of Directors Proven Track Record in Innovation with Extensive Operating Experience Dr. Neil Maresky CEO/BOARD MEMBER • Trained MD in Emergency Medicine and Family Practice • VP Scientific Affair
Slide 24: Newcourt Management Team
24 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Marc Balkin CHIEF EXECUTIVE OFFICER • Partner, DiGame • Former Partner, Hasso Plattner Ventures / Capital Emerging Markets • Served on and chaired investment committees of Enablis , First National Bank Vumela Fund,
Slide 25: Newcourt: Domain Experts in Partnership with Experienced SPAC Dealmakers
25 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Newcourt : Domain Experts in Partnership with Experienced SPAC Dealmakers PHOENIX BIOTECH ACQUISITION CORP. FTAC Olympus Acquisition Corp. $750mm merged with Payoneer Phoenix Biotech Acquisition Corp. $175mm SPAC Lo
Slide 26: Executive Summary
26 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Executive Summary Newcourt Acquisition Corp and Psyence entered into an Amended and Restated Business Combination Agreement on July 31st, 2023 • The Resulting cash in the Combined Company is anticipated to be approx
Slide 27: Risk Factors Relating to Psyence's Business
27 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature Risk Factors Relating to Psyence’s Business We are a clinical - stage biotechnology company and have incurred significant losses since our inception . We anticipate that we will incur significant losses for the fore
Slide 28: Contact: ir@psyence.com www.psyence.com
28 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature ir@psyence.com www.psyence.com